RxDoctor Payments Data

Jenny Placido Disla, MD

Cardiovascular Disease · Weston, FLNPI 1891182879

Payments from drug & device makers

$14,229in general payments, 2019–2025

Across 98 payments — averaging $145.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$8K
  • Edwards Lifesciences$3K
  • Boston Scientific$2K
  • Boehringer Ingelheim$266
  • Heartflow, Inc.$145
  • Pfizer$128
  • plus $579 from 10 others

What the payments were for

  • Speaking & faculty fees$5,10036%
  • Travel & lodging$3,70226%
  • Food & beverage$5,32937%
  • Education$991%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,229 in reported general payments places this provider in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$107,892
Medicare patients
863
Services billed
1,912

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban110$135,604
EntrestoSacubitril/Valsartan52$70,842
JardianceEmpagliflozin30$28,710
XareltoRivaroxaban22$21,369
FarxigaDapagliflozin Propanediol15$19,133
Ezetimibe40$2,749
Metoprolol Succinate138$1,776
Rosuvastatin Calcium157$1,688
Atorvastatin Calcium158$1,457
Valsartan11$662
Hydralazine Hcl34$626
Amlodipine Besylate118$624
Nifedipine ErNifedipine23$572
Losartan Potassium82$538
Diltiazem 24hr Er (Cd)Diltiazem Hcl12$528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$128$135,604110 claims
NovartisEntresto$120$70,84252 claims
Boehringer IngelheimJardiance$266$28,71030 claims
Johnson & JohnsonXarelto$128$21,36922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Weston

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →